A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: Data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

BMC Medicine

Volumn 6, Issue , 2008, Pages

  Vickers, Andrew J ^a   Cronin, Angel M ^a   Aus, Gunnar ^b   Pihl, Carl Gustav ^b   Becker, Charlotte ^c   Pettersson, Kim ^d   Scardino, Peter T ^a   Hugosson, Jonas ^b   Lilja, Hans ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; EUROPE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COUNSELING; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SWEDEN; UNNECESSARY PROCEDURE; VEIN PUNCTURE; BIOPSY; BLOOD; COMPARATIVE STUDY; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; STATISTICAL MODEL;

BIOPSY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SWEDEN;

EID: 48249152185     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-6-19     Document Type: Article

References (47)

1. Punglia RS D'Amico AV Catalona WJ Roehl KA Kuntz KM Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level Cancer 2006, 106:1507-1513. 10.1002/cncr.21766 16518812
2. Bozeman CB Carver BS Eastham JA Venable DD Treatment of chronic prostatitis lowers serum prostate specific antigen J Urol 2002 167, 1723-1726. 10.1016/S0022-5347(05)65186-5 11912396
3. Fadare O Wang S Mariappan MR Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens Arch Pathol Lab Med 2004, 128:557-560. 15086303
4. Jemal A Siegel R Ward E Murray T Xu J Smigal C Thun MJ Cancer statistics, 2006 CA Cancer J Clin 2006, 56:106-130. 16514137
5. Thompson IM Ankerst DP Chi C Lucia MS Goodman PJ Crowley JJ Parnes HL Coltman CA Jr Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower Jama 2005, 294:66-70. 10.1001/jama.294.1.66 15998892
6. Lee R Localio AR Armstrong K Malkowicz SB Schwartz JS A meta-analysis of the performance characteristics of the free prostate-specific antigen test Urology 2006, 67:762-768. 10.1016/j.urology.2005.10.052 16600352
7. Roddam AW Duffy MJ Hamdy FC Ward AM Patnick J Price CP Rimmer J Sturgeon C White P Allen NE Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis Eur Urol 2005, 48:386-399. 10.1016/ j.eururo.2005.08.012 15982797
8. Steuber T Nurmikko P Haese A Pettersson K Graefen M Hammerer P Huland H Lilja H Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen J Urol 2002 168, 1917-1922. 10.1016/S0022-5347(05)64263-2 12394676
9. Lein M Semjonow A Graefen M Kwiatkowski M Abramjuk C Stephan C Haese A Chun F Schnorr D Loening SA Jung K A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen J Urol 2005, 174:2150-2153. 10.1097/01.ju.0000181221.72017.ca 16280753
10. Mikolajczyk SD Catalona WJ Evans CL Linton HJ Millar LS Marker KM Katir D Amirkhan A Rittenhouse HG Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer Clin Chem 2004, 50:1017-1025. 10.1373/clinchem.2003.026823 15054080
11. Bangma CH Wildhagen MF Yurdakul G Schroder FH Blijenberg BG The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer BJU Int 2004, 93:720-724. 10.1111/ j.1464-410X.2003.04733.x 15049979
12. Martin BJ Cheli CD Sterling K Ward M Pollard S Lifsey D Mercante D Martin L Rayford W Prostate specific antigen isoforms and human glandular kallikrein 2 - which offers the best screening performance in a predominantly black population? J Urol 2006, 175:104-107. 10.1016/ S0022-5347(05)00069-8 16406882
13. Stephan C Jung K Lein M Sinha P Schnorr D Loening SA Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer Cancer Epidemiol Biomarkers Prev 2000, 9:1133-1147. 11097220
14. Nam RK Diamandis EP Toi A Trachtenberg J Magklara A Scorilas A Papnastasiou PA Jewett MA Narod SA Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen J Clin Oncol 2000, 18:1036-1042. 10694554
15. Becker C Piironen T Pettersson K Hugosson J Lilja H Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater Urology 2000, 55:694-699. 10.1016/ S0090-4295(99)00585-3 10792083
16. Martin BJ Finlay JA Sterling K Ward M Lifsey D Mercante D Jainto JM Martin L Rayford W Early detection of prostate cancer in African-American men through use of multiple biomarkers: Human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA) Prostate Cancer Prostatic Dis 2004, 7:132-137. 10.1038/sj.pcan.4500706 15007379
17. Nurmikko P Pettersson K Piironen T Hugosson J Lilja H Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146 Clin Chem 2001, 47:1415-1423. 11468231
18. Villanueva J Shaffer DR Philip J Chaparro CA Erdjument-Bromage H Olshen AB Fleisher M Lilja H Brogi E Boyd J Sanchez-Carbayo M Holland EC Cordon-Cardo C Scher HI Tempst P Differential exoprotease activities confer tumor-specific serum peptidome patterns J Clin Invest 2006, 116:271-284. 1323259 16395409 10.1172/JCI26022
19. Piironen T Pettersson K Suonpaa M Stenman UH Oesterling JE Lovgren T Lilja H In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples Urology 1996, 48(Suppl 6A):81-87. 10.1016/ S0090-4295(96)00616-4
20. Pilebro B Johansson R Damber L Damber JE Stattin P Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden Scand J Urol Nephrol 2003, 37:210-212. 10.1080/00365590310008064 12775278
21. Stattin P Johansson R Damber JE Hellstrom M Hugosson J Lundgren R Varenhorst E Johansson JE Non-systematic screening for prostate cancer in Sweden - survey from the National Prostate Cancer Registry Scand J Urol Nephrol 2003, 37:461-465. 10.1080/00365590310015778 14675917
22. Hugosson J Aus G Lilja H Lodding P Pihl CG Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma Cancer 2004, 100:1397-1405. 10.1002/cncr.20126 15042673
23. Aus G Bergdahl S Hugosson J Lodding P Pihl CG Pileblad E Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50-66 years. Implications for sampling order Eur Urol 2001, 39:655-661. 10.1159/000052523 11464054
24. Sobin LH Wittekind C UICC TNM Classification of Malignant Tumors New York: John Wiley & Sons 1997
25. Gleason DF Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma Urologic pathology: The prostate Philadelphia, PA: Lea and Febiger Tannenbaum M 1977, 171-198.
26. Ulmert D Becker C Nilsson JA Piironen T Bjork T Hugosson J Berglund G Lilja H Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C Clin Chem 2006, 52:235-239. 10.1373/clinchem.2005.050641 16384894
27. Pettersson K Piironen T Seppala M Liukkonen L Christensson A Matikainen MT Suonpaa M Lovgren T Lilja H Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex Clin Chem 1995, 41:1480-1488. 7586521
28. Piironen T Lovgren J Karp M Eerola R Lundwall A Dowell B Lovgren T Lilja H Pettersson K Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum Clin Chem 1996, 42:1034-1041. 8674186
29. Becker C Piironen T Kiviniemi J Lilja H Pettersson K Sensitive and specific immunodetection of human glandular kallikrein 2 in serum Clin Chem 2000, 46:198-206. 10657376
30. Vaisanen V Eriksson S Ivaska KK Lilja H Nurmi M Pettersson K Development of sensitive immunoassays for free and total human glandular kallikrein 2 Clin Chem 2004, 50:1607-1617. 10.1373/clinchem.2004.035253 15247158
31. Lilja H Ulmert D Bjork T Becker C Serio AM Nilsson JA Abrahamsson PA Vickers AJ Berglund G Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 2007, 25:431-436. 10.1200/ JCO.2006.06.9351 17264339
32. Nurmikko P Vaisanen V Piironen T Lindgren S Lilja H Pettersson K Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA Clin Chem 2000, 46:1610-1618. 11017939
33. Begg CB Greenes RA Assessment of diagnostic tests when disease verification is subject to selection bias Biometrics 1983, 39:207-215. 10.2307/2530820 6871349
34. Hunink MG Richardson DK Doubilet PM Begg CB Testing for fetal pulmonary maturity: ROC analysis involving covariates, verification bias, and combination testing Med Decis Making 1990, 10:201-211. 10.1177/ 0272989X9001000307 2370827
35. Vickers AJ Elkin EB Decision curve analysis: A novel method for evaluating prediction models Med Decis Making 2006, 26:565-574. 10.1177/ 0272989X06295361 17099194
36. Stata 9.2 and R http://www.R-project.org
37. Design library http://biostat.mc.vanderbilt.edu/s/Design
38. Durkan GC Sheikh N Johnson P Hildreth AJ Greene DR Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol BJU Int 2002, 89:33-39. 10.1046/j.1464-410X.2002.02555.x 11849157
39. Eskicorapci SY Baydar DE Akbal C Sofikerim M Gunay M Ekici S Ozen H An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer Eur Urol 2004, 45:444-449. 10.1016/j.eururo.2003.11.024 15041107
40. Guichard G Larre S Gallina A Lazar A Faucon H Chemama S Allory Y Patard JJ Vordos D Hoznek A Yiou R Salomon L Abbou CC de la Taille A Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients Eur Urol 2007, 52:430-435. 10.1016/ j.eururo.2007.02.062 17412489
41. Espana F Royo M Martinez M Enguidanos MJ Vera CD Estelles A Aznar J Jimenez-Cruz JF Heeb MJ Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples J Urol 1998, 160:2081-2088. 10.1016/ S0022-5347(01)62248-1 9817329
42. Catalona WJ Beiser JA Smith DS Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies J Urol 1997, 158:2162-2167. 10.1016/S0022-5347(01)68187-4 9366336
43. Catalona WJ Smith DS Ornstein DK Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements Jama 1997, 277:1452-1455. 10.1001/jama.277.18.1452 9145717
44. Steuber T Vickers A Haese A Kattan MW Eastham JA Scardino PT Huland H Lilja H Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy Int J Cancer 2007, 120:1499-1504. 10.1002/ ijc.22427 17205511
45. Thompson IM Chi C Ankerst DP Goodman PJ Tangen CM Lippman SM Lucia MS Parnes HL Coltman CA Jr Effect of finasteride on the sensitivity of PSA for detecting prostate cancer J Natl Cancer Inst 2006, 98:1128-1133. 16912265
46. Vaisanen V Peltola MT Lilja H Nurmi M Pettersson K Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments Anal Chem 2006, 78:7809-7815. 10.1021/ ac061201+ 17105175
47. Haese A Vaisanen V Finlay JA Pettersson K Rittenhouse HG Partin AW Bruzek DJ Sokoll LJ Lilja H Chan DW Standardization of two immunoassays for human glandular kallikrein 2 Clin Chem 2003, 49:601-610. 10.1373/ 49.4.601 12651813